
Alumis Inc (ALMS) Stock Forecast & Price Target
Alumis Inc (ALMS) Analyst Ratings
Bulls say
Alumis Inc has a robust pipeline with projected peak sales of $2 billion for its drug targeting Systemic Lupus Erythematosus (SLE), highlighting significant revenue potential, albeit with a conservative 20% probability ascribed for approval. The company's emphasis on leveraging its proprietary precision data analytics platform and a team experienced in precision medicine positions it well to navigate the challenges of drug development in autoimmune disorders. Additionally, the viability of ESK-001 for psoriatic arthritis, supported by positive data from a comparable treatment, further enhances the company's growth prospects.
Bears say
Alumis Inc faces significant risks that contribute to a negative outlook on its stock, prominently due to potential delays in advancing its lead candidate, ESK-001, into pivotal trials, which could impede its development timeline. Moreover, the possibility of ESK-001 failing to demonstrate efficacy in critical indications such as psoriasis (PsO) and systemic lupus erythematosus (SLE) represents a substantial hurdle to achieving market approval and subsequent revenue generation. Additional concerns include regulatory delays, competitive pressures within the inflammation and immunology (I&I) sector, and the risk of dilution, all of which could adversely impact shareholder value and undermine market confidence.
This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.
Alumis Inc (ALMS) Analyst Forecast & Price Prediction
Start investing in Alumis Inc (ALMS)
Order type
Buy in
Order amount
Est. shares
0 shares